Allogeneic hematopoietic transplantation is increasingly used in patients aged 55 years or more with AML. The question of whether outcomes can be improved with an allele-level 8/8 HLA-matched unrelated donor (MUD) rather than an older HLA-matched sibling (MSD, more than 55 years) is still unanswered. We thus analyzed outcomes in 714 patients aged 55 years and older with AML in first CR (CR1) who received PBSCs after a reduced-intensity conditioning hematopoietic cell transplant from a MUD (n = 310) or a MSD (n = 404) in a recent period (2005)(2006)(2007)(2008)(2009)(2010). The 3-year cumulative incidences (CIs) of non-relapse mortality were 17% and 23% with MSD and MUD, respectively (P = 0.17). The 3-year CIs of relapse were 37% and 30%, respectively (P = 0.12), resulting in a 3-year CI of leukemia-free survival of 46% and 47%, respectively (P = 0.51). The 3-year overall survival was 49% with both MSD and MUD.
INTRODUCTION
Today, allogeneic hematopoietic cell transplantation (HCT) is considered by many groups to be the best consolidation treatment in eligible elderly patients with AML achieving first CR (CR1). 1, 2 Some data indicated that outcome after HCT may be similar when using grafts from matched unrelated donors (MUDs) or matched sibling donors (MSDs), both in the standard myeloablative and reduced-intensity conditioning (RIC) HCT settings. [3] [4] [5] [6] However, the question of whether outcomes can be improved with an allele-level 8/8 HLA-MUD rather than an older HLA-MSD (more than 55 years) is still unanswered. One singlecenter study including 168 AML patients suggested that the use of an unrelated donor might be associated with an improved outcome post HCT compared with an older MSD. 7 Similar results were published by another single-center study of 442 patients, which included various hematological malignancies but only PBSC as the source of stem cells. 8 Conversely, another study from the Center for International Bone and Marrow Transplant Research (CIBMTR) including more than 2000 patients older than 50 years with different hematological malignancies (patients with AML, n = 904) did not suggest such an advantage, 9 in line with the Fred
Hutchinson Cancer Research Center experience published recently. 10 In daily practice, the use of unrelated donors implies less convenience, longer delay between CR1 to HCT and also less availability of donor lymphocyte infusions. This study aims to answer the question whether in patients older than 55 years with AML in CR1: we should search for a MUD when an old sibling donor is available.
PATIENTS AND METHODS Patients
This retrospective study was performed by the Acute Leukemia Working Party of the European group for Blood and Marrow Transplantation (EBMT). The EBMT registry is a voluntary working group of more than 500 transplant centers who enter detailed data on consecutive allogeneic and autologous hematopoietic cell transplantation into a shared data base called ProMISe (Project Manager Internet System). All patients provided written informed consent in accordance with the Declaration of Helsinki for data submission and research participation. The scientific board of the Acute Leukemia Working Party of EBMT approved this study. 
Inclusion criteria
Included are patients aged 55 years or older who were transplanted from 2005 to 2010 after a RIC regimen 11 for an AML in CR1. Patients with secondary AML were excluded. Two cohorts of patients were identified as: (1) recipients of an HLA-matched transplants with donors aged 55 years or older (MSD) and (2) recipients of an HLA-MUD age. All unrelated donorrecipient pairs were matched at HLA-A, -B, -C and -DRB1 at the allele level (8/8 HLA-match), and 291 were also matched at HLA-DQ allele level. HLA typing was performed prospectively by the EBMT center. Only patients who received filgrastim-mobilized PBSC grafts were included in this study.
End points
The primary end point was probability of overall survival (OS). Secondary study end points were leukemia-free survival (LFS), relapse incidence, cumulative incidences (CIs) of acute and chronic GVHD and non-relapse mortality (NRM). LFS was defined as survival in continuous CR. Relapse was defined as disease recurrence based on morphologic evaluation. NRM was defined as death after HCT without leukemia relapse. Standard clinical criteria were used to diagnose and grade GVHD. 12, 13 Time-to-event outcomes were counted from the date of transplantation to the date of event or date of last follow-up.
Statistical analysis
Patient-, disease-and transplant-related variables between MSD and MUD groups were compared, using the χ 2 or Fischer exact test for categorical variables and the Mann-Whitney test in cases of continuous variables. CI functions were used to estimate relapse incidence and NRM in a competing risks setting, because death and relapse compete with each other. 14, 15 To study acute and chronic GVHD, we considered death to be a competing event. Probability of LFS was calculated using the Kaplan-Meier estimate. Univariate analyses were performed using Gray's test for CI function and the log-rank test for LFS and OS. Multivariate analysis consisted in Cox proportional hazards model or Fine-Gray model for competing events. All tests were two-sided and P-values ⩽ 0.05 were considered as indicating significant association. Statistical analyses were performed with SPSS Software (SPSS, Inc., Chicago, IL, USA) and R 2.15.0 (R-Development Core Team, Vienna, Austria) software packages.
RESULTS

Patient, disease and transplant characteristics
Data of 714 adult de novo AML patients in CR1 aged 55 years or older transplanted in 132 institutions using either a MSD (n = 404) or a MUD (n = 310) were included in this study (median age 61.5 years; range 55-74 years). Patient characteristics are summarized in Table 1 . Disease risks were not different between groups. 16 Patients from the MUD group were transplanted with a longer time interval between diagnosis and HCT (P o 0.001), with a conditioning regimen including more antithymocyte globulin (ATG; P o 0.001), using a younger donor (P o0.001), received less frequently gender mismatch grafts (female donor/male recipient; Po 0.001) and donor/recipient CMV serostatus was more likely negative (P o 0.001).
Engraftment, acute and chronic GvHD The median follow-up was 37 months (range = 3-98) in the MSD group and 30 months (range = 3-89) in the MUD group. Almost all patients engrafted (394 in the MSD group (98%) versus 306 in the MUD group (99%)). Seven patients did not engraft in the MSD group compared with three in the MUD group (99%, P = 0.39). The CI of grade II-IV acute GvHD was 17% in the MSD group versus 25% in the MUD group, respectively (P = 0.008). A higher rate of acute II-IV GvHD was observed for patients aged more than 61.5 years (median age of the entire population, hazard ratio (HR) = 1.53 (95% confidence interval = 1.08-2.17), P = 0.02) and for patients who received a MUD transplantation (HR = 1.79 (95% confidence interval = 1.08-2.17), P = 0.003). However, the CI of chronic GvHD was similar between both groups (46% in the MSD group versus 47% in the MUD group, respectively, P = 0.79). The presence of ATGs in the conditioning regimen was the only factor, which significantly reduced this risk (HR = 0.55 (0.42-0.73), Po 0.001). Figure 1a ). In multivariate analysis, there was a trend for lower NRM in the presence of ATG in the conditioning regimen but this was not statistically significant (HR = 0.73 (0.51-1.05), P = 0.09 ( Table 2) .
The 3-year CI of relapse was similar between the MSD donor and the MUD group (37% in the MSD group versus 30% in the MUD group, respectively, P = 0.12). Poor-risk cytogenetics was the only factor associated with a significantly higher risk of relapse (HR = 1.70 (1.27-2.24), P = 0.0001; Table 2 ). Of note, chronic GvHD appears to be protective once introduced into the model as a time-dependent co-variable (HR = 0.59 (0.41-0.86), P = 0.006), whereas poor-risk cytogenetics was still associated with more relapse (HR = 1.84 (1.38-2.46), P = 0.00003). LFS at 3 years was 46% in the MSD group versus 47% in the MUD group, respectively, (P = 0.51; Figure 1b) . Poor-risk cytogenetics was the only factor associated with worse LFS (HR = 1.64 (1.31-2.06), P = 0.00002; Table 2 ).
The 3-year OS was 49%, similar between HLA-MSD and MUD (P = 0.81; Figure 1c ). Poor-risk cytogenetics was again the only factor associated with poorer OS (HR = 1.57 (95% confidence interval = 1.24-1.98); P = 0.0002, respectively; Table 2 ).
DISCUSSION
Because of improvement of life expectancy in general and reduction of risk from transplant, many elderly patients with AML are now considered for an HCT with curative intent. The goal of our study was to answer a clinically relevant question for recipients aged 55 years or more in the context of AML in CR1 who received PBSC after RIC HCT: whether use of a MUD would result in improved outcomes compared with use of an older MSD (⩾55 years). Our main finding is the absence of advantage on outcome to use a MUD versus a MSD aged 55 years or more in this setting. In our cohort, the most important factor impacting both relapse and OS was poor-risk cytogenetics.
Five previous recent studies including patients with AML or MDS already addressed the issue of donor age in the literature with controversial results. [7] [8] [9] [10] 17 Two studies did not find any difference between old MSD and MUD, 9,10 whereas the three others favored a MUD over a MSD. 7, 8, 17 It is important to note that the population being studied strongly influences the results. One report addressed patients with AML only but in a small group of patients, 7 one study included patients who were transplanted only with PBSCs, 8 another one, patients with MDS only, 17 whereas the final two included various hematological malignancies. 9, 10 One other important factor is the age limit of the selected populations. In general, if a patient is considered to be a candidate for HCT, a donor search is first performed among the siblings of the patient, who tend to have ages similar to the recipients. From a clinical point of view, sibling donors are more prone to chronic conditions at the age of 55 years or more, which is why this age limit was chosen, whereas all other previous published papers included also younger donors and recipients (o 55 years). Consequently, half of the patients published previously were transplanted with a standard conditioning regimen and 20% with bone marrow as the source of stem cells 7, 9, 17 except one study that included only PBSCs. 8 All our patients received only RIC regimen and PBSC, which may explain the disparity of the results. Finally, all our patients were transplanted in a recent period (2005 or after) to avoid as much as possible the bias of practice changing during time, whereas the other studies included patients transplanted before this date. For all these reasons, we believe the absence of advantage of outcome we found between a MUD and an older MSD ( ⩾ 55 years) is a factual picture of the reality in this particular population.
We did assess the impact of age within the MUD group and did not find any differences in term of outcome when this latter group was divided into two groups (less than 35 years old and 35 years old or more) and compared with the MSD group (data not shown). The only difference we found between the use of a MUD versus a MSD aged 55 years or more was a significantly higher rate of grade 2-4 acute GvHD, which is in accordance with the Fred Hutchinson Cancer Research Center report. 10 Greater genetic disparity with MUD, as well as diminished effector activity with older T cells 18, 19 may explain this finding. However, the CI of chronic GvHD at 2 years was similar between both groups. The presence of ATG in the conditioning regimen significantly reduced this risk and was eventually associated with a lower rate of NRM without reaching statistical significance. No large prospective randomized trials assessing the role of ATG have been undertaken in the RIC setting. One retrospective study on more than 1500 patients suggested that in vivo T-cell depletion lowers the risk of chronic GvHD at the expense of increased relapse rates, resulting in inferior disease-free survival. 20 ATG did not impact the 2-year CI of relapse in our study, which differs from the CIBMTR one in regard to patients' age (only 55 years and older), stem cell source (only PBSC), disease type and status (only AML in CR1), and donor compatibility (only matched donor). However, our results are in accordance with earlier report by other smaller studies, [21] [22] [23] as well as to a recent publication by our group on 1250 adult patients with de novo AML in CR1 given PBSC from HLA-identical siblings after chemotherapy-based RIC regimen, where the use of ATG and the use of alemtuzumab were each associated with a lower risk of chronic GVHD, but a similar risk of relapse. 24 Because of the selection criteria (only patients 8/8 matched were considered), we were unable to assess the impact of mismatches on the risk of chronic GvHD and eventually NRM. Moreover, the type and dose of ATG were unknown for a sizeable number of the patients in our study.
As already pointed out in previous studies of RIC regimens in patients with AML (for a review, see Blaise et al. 25 ), the leading cause of treatment failure was relapse. The current study showed higher relapse rates in patients with high-risk disease, which has already been published. 26 In our study, poor-risk cytogenetics was the only factor independently affecting relapse and eventually OS. This suggests that prior chemotherapy may affect posttransplantation outcome by effectively balancing the reduced strength of RIC regimens, which is in contrast to what was demonstrated several years ago in the standard setting. 27 However, when introducing chronic GvHD into the model as a time-dependent covariate, the only two factors, which remained independently associated with relapse, are chronic GvHD itself (more relapse if absent) and the poor-risk cytogenetics status. This result illustrates once again the difficulty using RIC regimen to settle a well-balanced dosage between the unique graft-versusleukemia effects related to chronic GvHD without impacting as much as possible the quality of life of recipients. Moreover, patients with high-risk disease continue to experience poor outcomes after RIC HCT. 25 Further developments of more intensive but low toxicity regimens might represent an opportunity. 28 Also after HCT, prophylactic donor lymphocyte infusion and/or targeted therapy may be another investigational direction. 29, 30 Our work has strengths and limitations. Our study is limited mainly due to its retrospective nature. An important limitation is Abbreviations: ATG = anti-thymocyte globulin; HCT = hematopoietic cell transplantation; MSD = matched sibling donor; MUD = matched unrelated donor.
Donor age and RIC HCT for patients with AMLits non-randomized setting, which offers the potential for the introduction of bias. Despite its retrospective nature, this study included a large number of homogeneous AML patients in CR1, who received RIC HCT and who were all aged 55 years or more. Overall, the current data suggest no outcome advantage for using a MUD versus MSD aged ⩾ 55 years. Therefore, until prospective trials are completed, HLA-identical donors (even aged 455 years if eligible for stem cell donation) should continue to be considered before MUD, when there is an indication for RIC HCT.
